Revenue: $63.8 million in Q1 2025, up 196% year-over-year. Net Product Revenue for ZORYVE: $68.3 million, reflecting a 196% growth year-over-year. Prescription Demand Growth: 10% increase compared to Q4 2024. Gross to Net Ratio: Remained in the 50% range. Cost of Sales: $8.8 million in Q1 2025. R&D Expenses: $17.5 million, down 24% from Q1 2024. SG&A Expenses: $64 million, up 17% year-over-year. Cash and Marketable Securities: $198.7 million as of March 31, 2025. Cash Burn from Operations: Approximately $30 million in Q1 2025. Total Debt: $107.6 million.

Warning! GuruFocus has detected 3 Warning Signs with ARQT.

Release Date: May 06, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) reported a significant year-over-year revenue growth of 196% for Q1 2025, reaching $63.8 million. The company achieved a 10% increase in prescription demand compared to Q4 2024, despite typical Q1 headwinds. ZORYVE's insurance coverage is robust, with approximately 80% of prescriptions being reimbursed. The company anticipates further growth with upcoming approvals for ZORYVE foam for scalp and body psoriasis and ZORYVE cream for atopic dermatitis in young children. Arcutis Biotherapeutics Inc (NASDAQ:ARQT) is seeing a shift in the market from topical steroids to non-steroidal treatments, positioning ZORYVE as a leading option.

Negative Points

Despite strong performance, Q1 revenues were slightly down by 2% compared to Q4 2024 due to typical first-quarter deductible resets and insurance changes. SG&A expenses increased by 17% year-over-year, reflecting higher promotional spending for current and upcoming launches. The company faces challenges in expanding ZORYVE's adoption in primary care, requiring more frequent engagements to build familiarity. There is uncertainty regarding the ongoing patent litigation with Padagis, although the stay provides temporary relief. The company anticipates some seasonality impact on ZORYVE's performance, particularly in the summer months.

Q & A Highlights

Q: What should we expect regarding the seasonality and cyclicality of ZORYVE's performance throughout the year? A: L. Todd Edwards, Chief Commercial Officer, mentioned that while there might be a modest seasonal impact over the summer months, the launch of ZORYVE foam for scalp and body psoriasis and the ongoing conversion from the steroid market are expected to drive revenue growth in 2025.

Q: Can you elaborate on the potential impact of the ZORYVE foam approval for scalp and body psoriasis on market expansion and utilization? A: L. Todd Edwards explained that they do not anticipate significant cannibalization of ZORYVE cream. The foam offers unique benefits for hair-bearing areas, which should lead to broader utilization. Frank Watanabe, CEO, added that the foam provides a new option for treating scalp psoriasis, which could drive further growth.

Story Continues

Q: How do you expect the gross-to-net trend to evolve throughout the year? A: L. Todd Edwards stated that while there was an impact on gross-to-net early in the first quarter due to deductible resets, improvements have been seen, and they expect to remain within the 50% range as the year progresses.

Q: What are the key learnings from ARQ-252 and oral baricitinib for ARQ-255 in alopecia areata? A: Patrick Burnett, Chief Medical Officer, noted that ARQ-255 is designed to deliver the drug down the hair follicle, overcoming challenges faced by ARQ-252. The focus is on achieving effective delivery to the target area, which is crucial for treating alopecia areata.

Q: How is the primary care and pediatric market being addressed, and what are the barriers to prescribing in these segments? A: L. Todd Edwards highlighted that Kowa is making steady progress in primary care and pediatrics, focusing on educating providers and staff about non-steroidal options. The primary care selling cycle requires frequent engagements to build familiarity, but positive signals are emerging.

Q: What is the current split of ZORYVE patients being treated in dermatology versus primary care settings? A: Frank Watanabe mentioned that while the patient population is split 50/50 between dermatology and non-dermatology settings, the business is currently overwhelmingly dermatology-focused. Over time, primary care and pediatrics are expected to become significant contributors to growth.

Q: How did Arcutis manage to avoid the typical seasonality in Q1 performance? A: L. Todd Edwards explained that despite the usual deductible resets and insurance changes, strong demand growth and the differentiation of the ZORYVE portfolio helped maintain performance. The portfolio effect and new-to-brand prescriptions contributed to the positive results.

Q: What are the next steps after the litigation stay with Padagis, and what is the status of ARQ-255 in alopecia areata? A: Frank Watanabe stated that the litigation stay is indefinite, and the reason for Padagis' request is unknown. Patrick Burnett noted that ARQ-255 aims to deliver the drug effectively to the hair follicle, addressing a key challenge in treating alopecia areata.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments